Healthcare provider profile · identity verified

Candace L Embry, M.D.

Family Practice · CORYDON, IN · NPI 1659311553

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	505	139
Montelukast Sodium	Montelukast Sodium	496	152
Lisinopril	Lisinopril	488	130
Amlodipine Besylate	Amlodipine Besylate	477	118
Levothyroxine Sodium	Levothyroxine Sodium	278	73
Omeprazole	Omeprazole	250	73
Metformin Hcl	Metformin Hcl	226	62
Gabapentin	Gabapentin	199	47
Hydrochlorothiazide	Hydrochlorothiazide	158	40
Meloxicam	Meloxicam	131	31
Metoprolol Succinate	Metoprolol Succinate	123	43
Atenolol	Atenolol	122	34
Potassium Chloride	Potassium Chloride	118	32
Rosuvastatin Calcium	Rosuvastatin Calcium	117	34
Losartan Potassium	Losartan Potassium	109	26
Simvastatin	Simvastatin	106	30
Prednisone	Prednisone	100	82
Alendronate Sodium	Alendronate Sodium	99	23
Escitalopram Oxalate	Escitalopram Oxalate	97	24
Pantoprazole Sodium	Pantoprazole Sodium	97	27
Pravastatin Sodium	Pravastatin Sodium	90	26
Furosemide	Furosemide	89	28
Jardiance	Empagliflozin	88	18
Allopurinol	Allopurinol	83	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	80	19
Fluticasone Propionate	Fluticasone Propionate	79	35
Clopidogrel	Clopidogrel Bisulfate	78	20
Duloxetine Hcl	Duloxetine Hcl	77	20
Bupropion Xl	Bupropion Hcl	76	21
Metoprolol Tartrate	Metoprolol Tartrate	76	22
Albuterol Sulfate Hfa	Albuterol Sulfate	69	20
Synthroid	Levothyroxine Sodium	69	17
Citalopram Hbr	Citalopram Hydrobromide	68	16
Quetiapine Fumarate	Quetiapine Fumarate	64	15
Fluoxetine Hcl	Fluoxetine Hcl	57	12
Alprazolam	Alprazolam	54	17
Eliquis	Apixaban	54	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	suppressed
Ozempic	Semaglutide	50	15
Diclofenac Sodium	Diclofenac Sodium	46	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	45	13
Oxybutynin Chloride Er	Oxybutynin Chloride	44	13
Xarelto	Rivaroxaban	42	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	40	37
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	38	suppressed
Hydralazine Hcl	Hydralazine Hcl	37	11
Triamcinolone Acetonide	Triamcinolone Acetonide	37	24
Trulicity	Dulaglutide	37	suppressed
Ezetimibe	Ezetimibe	35	11
Sertraline Hcl	Sertraline Hcl	35	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	34	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	33	26
Azithromycin	Azithromycin	32	30
Cephalexin	Cephalexin	31	20
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	31	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Warfarin Sodium	Warfarin Sodium	31	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Mounjaro	Tirzepatide	29	suppressed
Carvedilol	Carvedilol	27	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	26	suppressed
Meclizine Hcl	Meclizine Hcl	26	12
Lovastatin	Lovastatin	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	23	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Klor-Con M20	Potassium Chloride	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Tresiba Flextouch U-100	Insulin Degludec	22	suppressed
Amoxicillin	Amoxicillin	21	15
Pregabalin	Pregabalin	21	suppressed
Ranolazine Er	Ranolazine	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Famotidine	Famotidine	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Ibandronate Sodium	Ibandronate Sodium	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Valsartan	Valsartan	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Nebivolol Hcl	Nebivolol Hcl	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	13
Fluconazole	Fluconazole	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Clonazepam	Clonazepam	14	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	14	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Arnuity Ellipta	Fluticasone Furoate	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	suppressed
Finasteride	Finasteride	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Estradiol	Estradiol	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Sotalol	Sotalol Hcl	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	11	suppressed
Clindamycin Hcl	Clindamycin Hcl	11	11
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Glyburide	Glyburide	11	suppressed
Klor-Con M10	Potassium Chloride	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Trazodone Hcl	Trazodone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error